Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412

Lenalidomide combined with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) (R2CHOP) in untreated diffuse large B-cell lymphoma (DLBCL) has shown promising activity, particularly in the activated B-cell–like (ABC) subtype. Eastern Cooperative Oncology Group (ECOG)-A...

Descripción completa

Detalles Bibliográficos
Autores principales: Nowakowski, Grzegorz S., Hong, Fangxin, Scott, David W., Macon, William R., King, Rebecca L., Habermann, Thomas M., Wagner-Johnston, Nina, Casulo, Carla, Wade, James L., Nagargoje, Gauri G., Reynolds, C. M., Cohen, Jonathon B., Khan, Nadia, Amengual, Jennifer E., Richards, Kristy L., Little, R. F., Leonard, John P., Friedberg, Jonathan W., Kostakoglu, Lale, Kahl, Brad S., Witzig, Thomas E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2021
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078264/
https://www.ncbi.nlm.nih.gov/pubmed/33555941
http://dx.doi.org/10.1200/JCO.20.01375

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078264/
https://www.ncbi.nlm.nih.gov/pubmed/33555941
http://dx.doi.org/10.1200/JCO.20.01375

Ejemplares similares